


SARS-CoV-2-IN-36

Cat. No.:	HY-151988
Molecular Formula:	C ₁₇ H ₂₁ N ₅ O ₃
Molecular Weight:	343.38
Target:	SARS-CoV
Pathway:	Anti-infection
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	SARS-CoV-2-IN-36 is a potent SARS-CoV-2 Mpro (SARS-CoV) inhibitor with an IC ₅₀ of 2.37 μM and a K _d of 1.19 μM in enzymatic assays. SARS-CoV-2-IN-36 shows antiviral activity against UC-1074, RG2674, and NVDBB-2220 SARS-CoV-2 variants in Vero cells ^[1] .																																			
In Vitro	SARS-CoV-2-IN-36 (compound 58) inhibit the replication of the Wuhan (UC-1074), South African (RG2674), and UK (NVDBB-2220) SARS-CoV-2 variants, with IC ₅₀ values of 5.0 μM, 39.9 μM, and 5.2 μM, respectively. SARS-CoV-2-IN-36 alters cell morphology only at concentrations above ≥100 μM and does not inhibit Vero cell growth up to a concentration >100 μM ^[1] . SARS-CoV-2-IN-36 (compound 58) lacks antiviral activity against two herpesviruses (varicella-zoster virus and human cytomegalovirus) in human embryonic lung fibroblasts. SARS-CoV-2-IN-36 shows a very low cytotoxicity also against embryonic lung fibroblasts ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.																																			
In Vivo	PK analysis of plasma concentrations, with ± SD, after intranasal (IN) and oral (PO) administration in male C57BL6 mice ^[1] .																																			
	<table border="1"> <thead> <tr> <th>Route</th> <th>Dose (mg/kg)</th> <th>Concentration (mg/mL)</th> <th>Number of animals</th> <th>C_{max} (ng/mL)</th> <th>T_{max} (h)</th> <th>AUC_{t/dose} (h*kg*ng/mL/mg)</th> </tr> </thead> <tbody> <tr> <td>IN</td> <td>0.5</td> <td>1.0</td> <td>3</td> <td>177.97±26.15</td> <td>0.25±0.00</td> <td>188.05±32.52</td> </tr> <tr> <td>IN</td> <td>1.25</td> <td>2.5</td> <td>3</td> <td>325.95±42.45</td> <td>0.25±0.00</td> <td>150.62±23.80</td> </tr> <tr> <td>PO</td> <td>10</td> <td>10</td> <td>3</td> <td>22.72±4.42</td> <td>0.75±0.43</td> <td>3.07±0.92</td> </tr> <tr> <td>PO</td> <td>25</td> <td>2.5</td> <td>3</td> <td>33.67±3.42</td> <td>0.5±0.43</td> <td>2.00±0.51</td> </tr> </tbody> </table> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p>	Route	Dose (mg/kg)	Concentration (mg/mL)	Number of animals	C _{max} (ng/mL)	T _{max} (h)	AUC _{t/dose} (h*kg*ng/mL/mg)	IN	0.5	1.0	3	177.97±26.15	0.25±0.00	188.05±32.52	IN	1.25	2.5	3	325.95±42.45	0.25±0.00	150.62±23.80	PO	10	10	3	22.72±4.42	0.75±0.43	3.07±0.92	PO	25	2.5	3	33.67±3.42	0.5±0.43	2.00±0.51
Route	Dose (mg/kg)	Concentration (mg/mL)	Number of animals	C _{max} (ng/mL)	T _{max} (h)	AUC _{t/dose} (h*kg*ng/mL/mg)																														
IN	0.5	1.0	3	177.97±26.15	0.25±0.00	188.05±32.52																														
IN	1.25	2.5	3	325.95±42.45	0.25±0.00	150.62±23.80																														
PO	10	10	3	22.72±4.42	0.75±0.43	3.07±0.92																														
PO	25	2.5	3	33.67±3.42	0.5±0.43	2.00±0.51																														

REFERENCES

[1]. Simone Di Micco, et al. Rational design of the zonulin inhibitor AT1001 derivatives as potential anti SARS-CoV-2. Eur J Med Chem. 2022 Dec 15;244:114857.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA